TITLE

Treatment of extensive ischemic cardiomyopathy: quality of life following two different surgical strategies

AUTHOR(S)
Cotrufo, Maurizio; Romano, GianPaolo; De Santo, Luca S.; Corte, Alessandro Della; Amarelli, Cristiano; Cafarella, Giuseppe; Maiello, Ciro; Scardone, Michelangelo
PUB. DATE
March 2005
SOURCE
European Journal of Cardio-Thoracic Surgery;Mar2005, Vol. 27 Issue 3, p481
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Abstract: Objective: To review outcomes and quality of life following two surgical strategies for severe left ventricular dysfunction due to ischemic dilated cardiomyopathy. Methods: Hospital and follow-up records of 111 patients with extensive ischemic cardiomyopathy (mean age 57.3±8.4) referring to our institution between January 1996 and December 2003 were reviewed. Group A included 42 patients (mean age 62.4±7.9) with morphological and functional cardiac parameters allowing for ventricular restoration (including endoventricular circular patch plasty, coronary artery by-pass grafting, and, when needed, mitral surgery). Group B included 69 patients (mean age 54.3±7.2), undergoing cardiac transplantation. Hospital mortality, treatment-related late mortality, incidence of cardiac events, freedom from cardiac failure, freedom from hospital re-admission, functional recovery at follow-up (3075.2pts/months; 100% complete) and quality of life (WHOQOL test) were assessed. Results: Hospital mortality was 19% in group A and 8.7% in group B (P=0.143). No treatment-related late deaths were observed in group A, while six deaths (9.5%) occurred in group B (P=0.063). Incidence of cardiac events was comparable. At 60 months, freedom from cardiac failure was 93.5±0.04 and 86.2±0.05%, respectively (P=0.23), freedom from hospital re-admission was 93.5±0.04 and 61.3±0.07% (P=0.002). Exertion dyspnea was present in 40% patients in group A versus 13% in group B (P=0.006). WHOQOL test showed a satisfying quality of life in both groups, although patients undergoing restoration reached higher scores in the psychological and social domains. Conclusions: Selected patients with ischemic cardiomyopathy, potentially eligible for transplantation, can be managed by ventricular restoration. In those patients post-operative quality of life is satisfactory, with comparable survival and low risk of re-hospitalization.
ACCESSION #
17436578

 

Related Articles

  • Naturopathic Management of Infections of the Heart and their Sequelae. Mikolai, Jeremy; Milner, Martin // Townsend Letter;May2012, Issue 346, p57 

    The article discusses the more common types of acute and chronic infectious heart diseases. It details the treatment of all types of chronic heart failure and cardiomyopathies using natural medicine and provides examples of real patient cases where the said medication was successfully practiced....

  • Recovery from Peripartum Cardiomyopathy in a Japanese Woman after Administration of Bromocriptine as a New Treatment Option. Abe, Takashi; Amano, Izuki; Sawa, Rintaro; Akira, Shigeo; Nakai, Akihito; Takeshita, Toshiyuki // Journal of Nippon Medical School;2010, Vol. 77 Issue 4, p226 

    Peripartum cardiomyopathy (PPCM) is a form of heart failure that occurs in women within 1 mouth before delivery and 5 mouths after delivery. The outcome of PPCM is variable but improves significantly when appropriate medication is administered in the acute phase; furthermore, the outcome does...

  • PSORIASIS AND CARDIOMYOPATHY: AN INTRIGUING ASSOCIATION. Prakash, Anupam // Indian Journal of Dermatology;Jul-Sep2010, Vol. 55 Issue 3, p271 

    A 25-year-old male symptomatic of heart disease for four months presented with biventricular failure. Echocardiography revealed dilated cardiomyopathy. He had skin lesions for 10 years which were clinically and histopathologically identified as psoriasis. Association of cardiomyopathy with...

  • CARDIOMYOPATHY. Lutz, Brobson // New Orleans Magazine;Feb2005, Vol. 39 Issue 5, p32 

    Focuses on cardiomyopathy or cardiac enlargement. Information on viral cardiomyopathy; Most common cause of heart failure in Louisiana; Leading cause of primary cardiomyopathy; Explanation on restrictive cardiomyopathy. INSET: Dr. John Walsh.

  • Cirrhotic cardiomyopathy. Soon Koo Baik; Fouad, Tamer R.; Lee, Samuel S. // Orphanet Journal of Rare Diseases;2007, Vol. 2, p15 

    Cirrhotic cardiomyopathy is the term used to describe a constellation of features indicative of abnormal heart structure and function in patients with cirrhosis. These include systolic and diastolic dysfunction, electrophysiological changes, and macroscopic and microscopic structural changes....

  • Ethnic differences in patient perceptions of heart failure and treatment: the West Birmingham heart failure project. Lip, G. Y. H.; Khan, H.; Bhatnagar, A.; Brahmabhatt, N.; Crook, P.; Davies, M. K. // Heart;Sep2004, Vol. 90 Issue 9, p1016 

    Objective: To investigate further the hypothesis that ethnic groups would have different levels of knowledge and perceptions of congestive heart failure (CHF) and treatments for this condition, a cross sectional survey was conducted of patients who were attending the heart failure clinics in two...

  • Heart failure in Africa: continuity or change? Bukhman, Gene // Heart;Aug2014, Vol. 100 Issue 16, p1223 

    The article reports on the heart failures in Africa. Topics discussed include deaths of older people from ischaemic heart disease, death of young people from coronary artery disease, and main aetiologies of heart failure including heart disease, cardiomyopathies and rheumatic heart disease...

  • Diagnostic and Prognostic Significance of Plasma N-Terminal-Pro-Brain Natriuretic Peptide in Decompensated Heart Failure with Preserved Ejection Fraction Paul, Biju; Soon, Kean H.; Dunne, James; De Pasquale, Carmine G. // Heart, Lung & Circulation;Dec2008, Vol. 17 Issue 6, p497 

    Background: Preserved ventricular function is increasingly recognised in CHF. Although, NTpro-BNP is a well-established diagnostic marker in heart failure with impaired EF, its significance in heart failure with preserved EF is unclear. NT pro-BNP is secreted from the ventricular wall and plasma...

  • Levosimendan: a decade of experience in Europe built on years of evidence. Parissis, John; Toller, Wolfgang; Franco, Fatima; Delgado, Juan F.; Danou, Fotini; Llorens-Soriano, Pere; Karpati, Peter C.J.; Nieminen, Markku S.; Mebazaa, Alexandre; Follath, Ferenc // European Journal of Heart Failure. Supplements;Jun2008, Vol. 7 Issue 2, p234 

    Abstract: Recent European Society of Cardiology''s (ESC) guidelines on the diagnosis and treatment of acute heart failure (AHF), suggest that an essential target in the management of these patients is to improve symptoms within hours, which should persist until hospital release, also protecting...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics